Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4295) 4295
rituximab (3925) 3925
science & technology (3603) 3603
life sciences & biomedicine (3571) 3571
female (2480) 2480
male (2439) 2439
middle aged (2078) 2078
antibodies, monoclonal, murine-derived (1986) 1986
adult (1725) 1725
aged (1637) 1637
treatment outcome (1426) 1426
antibodies, monoclonal - therapeutic use (1334) 1334
antibodies, monoclonal, murine-derived - therapeutic use (1300) 1300
hematology (1229) 1229
biological and medical sciences (1185) 1185
medical sciences (1182) 1182
oncology (1141) 1141
antibodies, monoclonal, murine-derived - adverse effects (1046) 1046
antineoplastic combined chemotherapy protocols - therapeutic use (972) 972
antibodies, monoclonal - adverse effects (970) 970
antibodies, monoclonal, murine-derived - administration & dosage (917) 917
antibodies, monoclonal - administration & dosage (706) 706
aged, 80 and over (659) 659
antineoplastic combined chemotherapy protocols - adverse effects (632) 632
antineoplastic agents - therapeutic use (593) 593
hematologic and hematopoietic diseases (573) 573
cyclophosphamide - administration & dosage (571) 571
immunologic factors - therapeutic use (571) 571
care and treatment (552) 552
antineoplastic agents - adverse effects (534) 534
retrospective studies (520) 520
antineoplastic agents (469) 469
immunosuppressive agents - therapeutic use (469) 469
adolescent (468) 468
lymphoma, large b-cell, diffuse - drug therapy (468) 468
abridged index medicus (467) 467
chemotherapy (462) 462
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (456) 456
cancer (450) 450
antineoplastic combined chemotherapy protocols - administration & dosage (449) 449
young adult (438) 438
rheumatology (436) 436
medicine & public health (433) 433
vincristine - administration & dosage (430) 430
transplantation (425) 425
recurrence (420) 420
lymphomas (417) 417
doxorubicin - administration & dosage (409) 409
disease-free survival (404) 404
remission induction (393) 393
drug therapy (392) 392
cyclophosphamide - adverse effects (387) 387
pharmacology. drug treatments (387) 387
prednisone - administration & dosage (385) 385
lymphoma (376) 376
prognosis (376) 376
immunology (374) 374
cyclophosphamide - therapeutic use (366) 366
follow-up studies (366) 366
risk factors (351) 351
drug administration schedule (338) 338
immunotherapy (326) 326
drug therapy, combination (325) 325
lymphoma, non-hodgkin - drug therapy (308) 308
child (299) 299
prednisone - therapeutic use (298) 298
antineoplastic agents - administration & dosage (294) 294
antimitotic agents (291) 291
lymphoma, b-cell - drug therapy (289) 289
vincristine - adverse effects (287) 287
immunologic factors - adverse effects (286) 286
doxorubicin - adverse effects (281) 281
time factors (281) 281
b-lymphocytes - immunology (280) 280
research (274) 274
arthritis, rheumatoid - drug therapy (273) 273
antirheumatic agents - therapeutic use (271) 271
health aspects (268) 268
prednisone - adverse effects (267) 267
antigens, cd20 - immunology (263) 263
animals (262) 262
immunosuppressive agents - adverse effects (256) 256
combined modality therapy (253) 253
monoclonal antibodies (253) 253
lymphoma, follicular - drug therapy (252) 252
leukemia, lymphocytic, chronic, b-cell - drug therapy (250) 250
tumors (249) 249
b-lymphocytes - drug effects (244) 244
vincristine - therapeutic use (236) 236
antirheumatic agents - adverse effects (235) 235
cyclophosphamide (231) 231
doxorubicin - therapeutic use (227) 227
prospective studies (220) 220
general & internal medicine (219) 219
rheumatoid arthritis (219) 219
analysis (217) 217
medicine, general & internal (210) 210
survival analysis (210) 210
hemic and lymphatic diseases (200) 200
immunologic factors - administration & dosage (199) 199
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4196) 4196
Japanese (49) 49
German (39) 39
Spanish (37) 37
French (34) 34
Chinese (29) 29
Italian (14) 14
Russian (10) 10
Polish (6) 6
Portuguese (6) 6
Croatian (5) 5
Danish (5) 5
Czech (4) 4
Hungarian (4) 4
Dutch (3) 3
Finnish (2) 2
Hebrew (2) 2
Norwegian (2) 2
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Management of noninfectious mixed cryoglobulinemia vasculitis: Data from 242 cases included in the CryoVas survey
by Terrier, Benjamin and Krastinova, Evguenia and Marie, Isabelle and Launay, David and Lacraz, Adeline and Belenotti, Pauline and De Saint-Martin, Luc and Quemeneur, Thomas and Huart, Antoine and Bonnet, Fabrice and Le Guenno, Guillaume and Kahn, Jean-Emmanuel and Hinschberger, Olivier and Rullier, Patricia and Diot, Elisabeth and Lazaro, Estibaliz and Bridoux, Frank and Zénone, Thierry and Carrat, Fabrice and Hermine, Olivier and Léger, Jean-Marc and Mariette, Xavier and Senet, Patricia and Plaisier, Emmanuelle and Cacoub, Patrice
Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 25, pp. 5996 - 6004
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Immunopathology | Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis | Biological and medical sciences | Immunoglobulinopathies | Medical sciences | Immunodeficiencies. Immunoglobulinopathies | Vasculitis - epidemiology | Infections - complications | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Data Collection | Cryoglobulinemia - complications | Vasculitis - complications | Cryoglobulinemia - epidemiology | Female | Retrospective Studies | Infections - epidemiology | Vasculitis - therapy | Cryoglobulinemia - therapy | Rituximab | Treatment Outcome | Combined Modality Therapy | Infections - therapy | Adrenal Cortex Hormones - adverse effects | Algorithms | Antibodies, Monoclonal - administration & dosage | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Adrenal Cortex Hormones - administration & dosage | Cohort Studies | Index Medicus | Abridged Index Medicus | Cryoglobulinemia | Antibodies, Monoclonal, Murine-Derived | Adrenal Cortex Hormones | Antibodies, Monoclonal | Infection | Life Sciences | Vasculitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
by Specks, Ulrich and Merkel, Peter A and Seo, Philip and Spiera, Robert and Langford, Carol A and Hoffman, Gary S and Kallenberg, Cees G.M and St. Clair, E. William and Fessler, Barri J and Ding, Linna and Viviano, Lisa and Tchao, Nadia K and Phippard, Deborah J and Asare, Adam L and Lim, Noha and Ikle, David and Jepson, Brett and Brunetta, Paul and Allen, Nancy B and Fervenza, Fernando C and Geetha, Duvuru and Keogh, Karina and Kissin, Eugene Y and Monach, Paul A and Peikert, Tobias and Stegeman, Coen and Ytterberg, Steven R and Mueller, Mark and Sejismundo, Lourdes P and Mieras, Kathleen and Stone, John H and RAVE-ITN Res Grp and RAVE-ITN Research Group
The New England journal of medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 5, pp. 417 - 427
WEGENERS-GRANULOMATOSIS | MAINTENANCE | ANTIBODY-ASSOCIATED VASCULITIS | RENAL VASCULITIS | CYCLOPHOSPHAMIDE | RITUXIMAB | ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES | RANDOMIZED-TRIAL | SYSTEMIC VASCULITIDES | CELL-ACTIVATION | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis | Recurrence | Azathioprine - therapeutic use | Glucocorticoids - therapeutic use | Double-Blind Method | Drug Administration Schedule | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | B-Lymphocytes | Rituximab | Cyclophosphamide - adverse effects | Remission Induction | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy | Cyclophosphamide - therapeutic use | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Drug Therapy, Combination | Antibodies, Monoclonal, Murine-Derived - adverse effects | Azathioprine - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Immunologic Factors - therapeutic use | Immunosuppression | Vasculitis | Drug therapy | Patient outcomes | Disease | Medical treatment | Hypersensitivity | Patients | Immunosuppressive agents | Cyclophosphamide | Infectious diseases | Lymphocytes B | Antineutrophil cytoplasmic antibodies | Remission | Azathioprine | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Treatment of Older Patients with Mantle-Cell Lymphoma
by Kluin-Nelemans, H.C and Hoster, E and Hermine, O and Walewski, J and Trneny, M and Geisler, C.H and Stilgenbauer, S and Thieblemont, C and Vehling-Kaiser, U and Doorduijn, J.K and Coiffier, B and Forstpointner, R and Tilly, H and Kanz, L and Feugier, P and Szymczyk, M and Hallek, M and Kremers, S and Lepeu, G and Sanhes, L and Zijlstra, J.M and Bouabdallah, R and Lugtenburg, P.J and Macro, M and Pfreundschuh, M and Procházka, V and Di Raimondo, F and Ribrag, V and Uppenkamp, M and André, M and Klapper, W and Hiddemann, W and Unterhalt, M and Dreyling, M.H
The New England journal of medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, pp. 520 - 531
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
by Trappe, Ralf, Dr and Oertel, Stephan, MD and Leblond, Veronique, Prof and Mollee, Peter, MBBS and Sender, Monica, MD and Reinke, Petra, Prof and Neuhaus, Ruth, MD and Lehmkuhl, Hans, MD and Horst, Heinz August, Prof and Salles, Gilles, Prof and Morschhauser, Franck, MD and Jaccard, Arnaud, Prof and Lamy, Thierry, Prof and Leithäuser, Malte, MD and Zimmermann, Heiner, MB BChir and Anagnostopoulos, Ioannis, Prof and Raphael, Martine, Prof and Riess, Hanno, Prof and Choquet, Sylvain, MD and the European PTLD Network and for the German PTLD Study Group and European PTLD Network and German PTLD Study Grp and German PTLD Study Group
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 196 - 206
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Organ Transplantation - pathology | Cyclophosphamide - therapeutic use | Epstein-Barr Virus Infections - therapy | Vincristine - administration & dosage | Adult | Female | Herpesvirus 4, Human - pathogenicity | Prednisolone - therapeutic use | France | Lymphoproliferative Disorders - etiology | Doxorubicin - administration & dosage | Antigens, CD20 - immunology | Rituximab | Lymphoproliferative Disorders - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Organ Transplantation - adverse effects | Adolescent | Vincristine - therapeutic use | Epstein-Barr Virus Infections - diagnosis | Lymphoproliferative Disorders - drug therapy | Aged | Germany | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Organ transplant recipients | Clinical trials | Product development | Epstein-Barr virus | Universities and colleges | Prednisolone | Cancer | Index Medicus | Antibodies, Monoclonal, Murine-Derived | Antigens, CD20 | Lymphoproliferative Disorders | Antineoplastic Combined Chemotherapy Protocols | Organ Transplantation | Vincristine | Doxorubicin | Herpesvirus 4, Human | Life Sciences | Immunology | Epstein-Barr Virus Infections
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
by Rummel, Mathias J, Prof Dr and Niederle, Norbert, Prof and Maschmeyer, Georg, Prof and Banat, G Andre, MD and von Grünhagen, Ulrich, MD and Losem, Christoph, MD and Kofahl-Krause, Dorothea, MD and Heil, Gerhard, Prof and Welslau, Manfred, MD and Balser, Christina, MD and Kaiser, Ulrich, Prof and Weidmann, Eckhart, Prof and Dürk, Heinz, MD, PhD and Ballo, Harald, MD and Stauch, Martina, MD and Roller, Fritz, MD and Barth, Juergen, Pharm and Hoelzer, Dieter, Prof and Hinke, Axel, PhD and Brugger, Wolfram, Prof and Study Grp Indolent Lymphomas StiL and Study group indolent Lymphomas (StiL)
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology | Lymphoma | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
by Cuccuini, Wendy and Briere, Josette and Mounier, Nicolas and Voelker, Hans-Ullrich and Rosenwald, Andreas and Sundstrom, Christer and Cogliatti, Sergio and Hirchaud, Edouard and Ysebaert, Loic and Bron, Dominique and Soulier, Jean and Gaulard, Philippe and Houlgatte, Remi and Gisselbrecht, Christian and Thieblemont, Catherine
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma
by Lamy, Thierry and Damaj, Gandhi and Soubeyran, Pierre and Gyan, Emmanuel and Cartron, Guillaume and Bouabdallah, Krimo and Gressin, Remy and Cornillon, Jerome and Banos, Anne and Le Du, Katell and Benchalal, Mohamed and Moles, Marie-Pierre and Le Gouill, Steven and Fleury, Joel and Godmer, Pascal and Maisonneuve, Herve and Deconinck, Eric and Houot, Roch and Laribi, Kamel and Marolleau, Jean Pierre and Tournilhac, Olivier and Branger, Bernard and Devillers, Anne and Vuillez, Jean Philippe and Fest, Thierry and Colombat, Philippe and Costes, Valérie and Szablewski, Vanessa and Bene, Marie C and Delwail, Vincent and LYSA Grp and LYSA Group
Blood, ISSN 0006-4971, 01/2018, Volume 131, Issue 2, pp. 174 - 181
Life Sciences & Biomedicine | Hematology | Science & Technology | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Vincristine - administration & dosage | Female | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Lymphoma, Large B-Cell, Diffuse - pathology | Kaplan-Meier Estimate | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Vincristine - therapeutic use | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
by Shpilberg, O and Jackisch, C
British journal of cancer, ISSN 0007-0920, 09/2013, Volume 109, Issue 6, pp. 1556 - 1561
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Antibodies, Monoclonal, Humanized - adverse effects | Lymphoma, Follicular - drug therapy | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antibodies, Monoclonal, Murine-Derived - chemistry | Recombinant Proteins - chemistry | Rituximab | Male | Antineoplastic Agents - administration & dosage | Recombinant Proteins - adverse effects | Hyaluronoglucosaminidase - chemistry | Recombinant Proteins - administration & dosage | Hyaluronoglucosaminidase - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Injections, Subcutaneous | Antineoplastic Agents - blood | Hyaluronoglucosaminidase - administration & dosage | Female | Antibodies, Monoclonal, Murine-Derived - adverse effects | Trastuzumab | Antibodies, Monoclonal, Humanized - chemistry | Index Medicus | trastuzumab | hyaluronidase | lymphoma | subcutaneous administration | breast cancer | Clinical Study | rituximab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study
by Flinn, Ian W and Van Der Jagt, Richard and Kahl, Brad S and Wood, Peter and Hawkins, Tim E and MacDonald, David and Hertzberg, Mark and Kwan, Yiu-Lam and Simpson, David and Craig, Michael and Kolibaba, Kathryn and Issa, Samar and Clementi, Regina and Hallman, Doreen M and Munteanu, Mihaela and Chen, Ling and Burke, John M
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 19, pp. 2944 - 2952
Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Peripheral Nervous System Diseases - chemically induced | Nausea - chemically induced | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Paresthesia - chemically induced | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Vomiting - chemically induced | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Alopecia - chemically induced | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights